Select Bibliography

Filter by any of these (after searching):

Qu, Xueping

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 13 items

Her2 gene expression and not Her2 amplification is predictive and prognostic in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Battaglin, Francesca , Ou, Fang-Shu , Qu, Xueping ... - ASCO - J Clin Oncol - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Innocenti, Federico , Ou, Fang-Shu , Qu, Xueping , Zemla, Tyler J. ... - - J Clin Oncol - 2019

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-80405

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-80405

Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance)

Innocenti, Federico , Rashid, Naim , Mu, Wancen , Ou, Fang-Shu ... - ESMO - Annals of Oncology - 2019

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Innocenti, Federico , Yazdani, Akram , Qu, Xueping , Ou, Fang-Shu ... - ASCO - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.

Innocenti, Federico , Yazdani, Akram , Rashid, Naim , Qu, Xueping ... - - Clin Cancer Res - 2022

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Johnson, Radia M. , Qu, Xueping , Lin, Chu-Fang , Huw, Ling-Yuh ... - - Nat Commun - 2022

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405 , Alliance-A152108

ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC (Alliance)

Johnson, Radia M. , Qu, Xueping , Thomas, Joshua , Kschonsak, Yvonne ... - AACR - Cancer Res - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P. ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P ... - - J Clin Oncol - 2019

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - Alliance-A151425 , CALGB-80405

Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Venook, Alan P. , Ou, Fang-Shu , Innocenti, Federico ... - ASCO - J Clin Oncol - 2017

Abstract - Secondary - Primary - GI - CALGB-80405

Identifying strong instrumental variables for pleiotropic assessment in Mendelian randomization: CALGB/SWOG 80405 (Alliance)

Yazdani, Akram , Lenz, Heinz-Josef , Pillonetto, Gianluigi ... - ASHG - - 2022

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-80405

Treatment-specific gene regulatory pathways in colorectal cancer patients (Alliance)

Yazdani, Akram , Lenz, Heinz-Josef , Qu, Xueping ... - ASHG - - 2021

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405